CELL INTELLIGENCE · 肿瘤细胞治疗研究

辐照 CD19 嵌合抗原受体 YTS 细胞保留抗肿瘤活性并可作为自体 CAR-T 疗法的可规模化替代方案

Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.

CAR-T 细胞治疗在肿瘤免疫治疗中的应用——生物学、临床成功与新兴挑战：综述

CAR-T cell therapy in cancer immunotherapy - Biology, clinical successes, and emerging challenges: A review.

通过红细胞介导的 mRNA 递送在体内生成 CAR 髓系细胞用于癌症免疫治疗

In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy.

CAR-NK 细胞疗法：实体瘤中的前景与挑战

CAR-NK cell therapy: promise and challenges in solid tumors.

NKG7 异位表达增强 CAR-T 功能并改善血液和实体瘤治疗疗效

Ectopic expression of NKG7 enhances CAR-T function and improves the therapeutic efficacy in liquid and solid tumors.

工程化 NKG2C (+) NK 样 T 细胞展现更优抗肿瘤疗效并减轻细胞因子释放综合征

Engineered NKG2C (+) NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome.

MUC1 靶向 CAR-NK 细胞抗人舌鳞状细胞癌的疗效

Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma.

靶向 MUC1 的 CAR-NK 细胞对人 OTSCC 具有显著疗效，其令人期待的治疗反应值得进一步开展临床试验。

规划通往实体瘤的杀伤路径：在肿瘤微环境中招募并激活 NK 细胞的策略

Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.

利用 CAR NK 细胞抗击肿瘤的技巧：综述

The tricks for fighting against cancer using CAR NK cells: A review.

血液肿瘤患者和医护人员接种第三剂 SARS-CoV-2 疫苗：免疫应答与不良事件——一项回顾性队列研究

Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events - a retrospective coh

这项在癌症患者中进行的研究显示，接种第三剂疫苗后抗体水平提高，且副作用可接受。抗体水平低于对照组，这凸显了进一步随访研究和专门试验的必要性。